FILING ANALYSIS · TUESDAY, NOVEMBER 10
InMed Pharmaceuticals Inc. INM — 8-K: Entry into a Material Definitive Agreement
negative
InMed Pharmaceuticals has effectively been acquired by Mentari via a merger, with Mentari securityholders owning approximately 99.0% of the capital stock post-merger, indicating significant dilution for existing InMed shareholders.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →